Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) and Emergent Biosolutions (NYSE:EBS – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.
Insider and Institutional Ownership
95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 6.0% of Emergent Biosolutions shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Amylyx Pharmaceuticals and Emergent Biosolutions’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amylyx Pharmaceuticals | N/A | -41.54% | -38.91% |
| Emergent Biosolutions | -40.16% | -0.43% | -0.15% |
Analyst Ratings
This is a breakdown of current ratings and target prices for Amylyx Pharmaceuticals and Emergent Biosolutions, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amylyx Pharmaceuticals | 1 | 0 | 6 | 2 | 3.00 |
| Emergent Biosolutions | 2 | 1 | 3 | 0 | 2.17 |
Amylyx Pharmaceuticals currently has a consensus price target of $43.71, suggesting a potential upside of 44.32%. Emergent Biosolutions has a consensus price target of $10.00, suggesting a potential upside of 72.27%. Given Emergent Biosolutions’ higher possible upside, analysts clearly believe Emergent Biosolutions is more favorable than Amylyx Pharmaceuticals.
Volatility & Risk
Amylyx Pharmaceuticals has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500. Comparatively, Emergent Biosolutions has a beta of 2.37, indicating that its stock price is 137% more volatile than the S&P 500.
Earnings and Valuation
This table compares Amylyx Pharmaceuticals and Emergent Biosolutions”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amylyx Pharmaceuticals | $87.37 million | 44.57 | -$144.74 million | ($1.44) | -21.03 |
| Emergent Biosolutions | $742.90 million | 0.40 | $52.60 million | ($5.10) | -1.14 |
Emergent Biosolutions has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.
Summary
Amylyx Pharmaceuticals beats Emergent Biosolutions on 8 of the 14 factors compared between the two stocks.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
About Emergent Biosolutions
Emergent BioSolutions is a biopharmaceutical company focused on products that address public health threats and medical emergencies. Its portfolio includes vaccines and treatments for infectious diseases, opioid overdose and other health risks, with customers that include governments and healthcare providers. Products associated with the company include BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; and NARCAN, a naloxone nasal spray used to reverse opioid overdose. Emergent also provides contract development and manufacturing services for pharmaceutical and biotechnology organizations.
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
